NCT07219420

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

Conditions

• Palmoplantar Pustulosis

Interventions

Type	Name	Description
DRUG	Bimekizumab	Study participants will receive bimekizumab at pre-specified time points.
DRUG	Placebo	Study participants will receive matching placebo at pre-specified time points.

Timeline

• Start date: 2025-11-14
• Primary completion: 2027-12-27
• Completion: 2029-11-22
• First posted: 2025-10-21
• Last updated: 2026-04-13

Locations

41 sites across 9 countries: Canada, China, Denmark, Germany, Hungary, Italy, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study